Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-31 · accession 0001883850-22-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-01 | 2022-03-31 | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $700.99 | -8,654 | 21.6K | -29% | -$6.07M |
| DM | 2022-04-01 | 2022-03-31 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $317.97 | +12.0K | 31.6K | +61% | +$3.82M |
| DM | 2022-04-01 | 2022-03-31 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -12.0K | 12.4K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | F | D | 6,857 | $700.99 | 24,771 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-31 | M | A | 2,000 | $555.67 | 23,425 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-31 | F | D | 1,797 | $700.99 | 21,628 | D | — | — | |
| 4 | Common | Common Stock | 2022-03-31 | M | A | 10,000 | $270.43 | 31,628 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-31 | M | D | 10,000 | $0.00 | 10,000 | D | $270.43 · — to 2023-12-13 | 10,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-31 | M | D | 2,000 | $0.00 | 12,450 | D | $555.67 · — to 2025-12-16 | 2,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |